Catalyst Bioscience, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration, a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, which has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition, it has two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, which is in advanced preclinical development, and a Factor Xa variant, which is in the advanced lead stage of development. Its second area of focus is regulation of the complement cascade.